Carmell Corp (Nasdaq: CTCX) announced the appointment of Kendra Bracken-Ferguson as CEO effective July 30, 2024 with Rajiv Shukla continuing as Chairman.
FLAGSTAFF, Ariz., Sept. 12, 2023 /PRNewswire/ -- Moonshot is excited to announce that its incubator client, Axolotl Biologix, based in its NACET Flagstaff, Arizona campus, has finalized a merger with Carmell Therapeutics (Nasdaq: CTCX). This partnership signifies a monumental step in regenerative medicine, notably in the sectors of active soft tissue repair, aesthetics, and orthopedic indications.
PITTSBURGH, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX) (œCarmell), a regenerative care company, today announced the completion of post-merger integration with...
Carmell Announces Successful Closing of Merger with Axolotl Biologix and Launch of a New Brand Identity
Carmell Therapeutics Announces Merger with Axolotl Biologix, a Profitable Regenerative Medicine Company
Pittsburgh-based Carmell Therapeutics has decided to take on a SPAC partner to go public after it filed its draft papers with the SEC in September for an IPO.
NEW YORK & PITTSBURGH--(BUSINESS WIRE)--Alpha Healthcare Acquisition Corp. III (Nasdaq: ALPA) (“ALPA”), a special purpose acquisition company led by Mr. Rajiv Shukla, today announced the execution of a definitive business combination agreement with Carmell Therapeutics Corporation (“Carmell™”), a Phase 2-stage biotechnology platform company developing allogeneic plasma-based biomaterials for bone and soft tissue healing indications.
Carmell Therapeutics Gains Alignment with FDA on a Path Forward to Evaluate the Use of Its Lead Product, a Bone Healing Accelerant, in Foot and Ankle Fusion Surgery
PITTSBURGH--(BUSINESS WIRE)--Carmell Therapeutics, a pioneering company in the development and commercialization of innovative Plasma-based Bioactive Materials (PBMs) to accelerate bone and soft tissue healing, today announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the “SEC”) relating to the proposed public listing of its Class A common stock. The public listing is expected to take place after the SEC completes its review process, subject to market and other conditions.
PITTSBURGH--(BUSINESS WIRE)--Carmell Therapeutics, a pioneering company in the development and commercialization of innovative Plasma-based Bioactive Materials (PBMs) to accelerate bone and soft tissue healing, today announced that Sebastian “Sebby” Borriello joined the company as Chief Business Officer. Carmell Therapeutics has a unique biologic solution that addresses unmet needs in bone and soft tissue treatment and utilizes an innovative, proprietary platform that accelerates and enhances healing, reduces complications, and enables patients to get back to their daily lives more quickly.